Posted by Michael Wonder on 02 Jul 2024
Idorsia’s Jeraygo (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
1 July 2024 - Jeraygo is a new oral antihypertensive therapy – the first in almost 40 years – that is working via a new therapeutic pathway.
Idorsia announced today that the European Commission has approved Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.
